Rezolute Inc
RZLT
Get informed when a big investor buys or sells
+ FollowMarket Cap$386.13M
Close$
$0.09
97.7% downside
Current Fair Value
97.7% downsideOvervalued by 97.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $386.13 Million |
|---|---|
| Enterprise Value | $375.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.75 |
| Beta | 0.61 |
| Outstanding Shares | 104,488,000 |
Return
| Return on Equity | -77.06% |
|---|---|
| Return on Assets | -68.75% |
| Return on Invested Capital | -31.74% |
Valuation & Multiples
| P/E Ratio | -5.28 |
|---|---|
| PEG | 33.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.49 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 24, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$1.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0472▼ 3.34% |
|---|---|
| Total Calls | 2,837,100▲ 99.40% |
| Total Puts | 133,900▲ 16.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.95%▲ 0.99% |
|---|---|
| Total Invested | $454.04M▲ 72.48% |
| Investors Holding | 152▲ 20.00% |
ESG Score
No data
About Rezolute Inc
23 employees
CEO: Nevan Elam Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline a...